With regard to the clinical setting in which PSMA radioligand imaging was employed, in eight studies, PET/CT had the purpose of staging untreated RCC patients [50,52,53,60,61,62], in two it had the purpose of restaging after surgery [56,57], in two it had the purpose of restaging after suspect findings in other radiological exams [48,52], while in one it had the purpose of assessing treatment response [58], and in the remaining three examined papers, both staging and restaging PET/CT exams were included [51,54,63]. The gene discussed is FOLH1; the disease is renal cell adenocarcinoma.